Study of Effects of YisuiShengxueGranules on Thalassemia

• Status: Completed
• Trial end date: 2012-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary objectives of this study are to evaluate whether Yisui Shengxue Granules therapy can increase the hemoglobin level in peripheral blood and alleviate the symptoms, and at the same time, evaluate its safety in the treatment of Thalassemia with the syndrome of deficiency of liver-yin and kidney-yin, and asthenia of essence and blood.

• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Guang'anmen Hospital of China Academy of Chinese Medical Sciences

Criteria

Inclusion Criteria:

1. Intermedia α-Thalassemia; intermedia β-Thalassemia; severe β-Thalassemia.

2. Syndrome of Deficiency of Liver-yin and Kidney-yin, and Asthenia of Essence and Blood.

3. Male or female, 3-40 years of age.

4. Provision of written informed consent.

Exclusion Criteria:

1. Complications with critical illness such as cerebrovascular disease, cardiovascular disease, hepatic disease, renal disease, malignancy and etc.

2. Allergy to any ingredients of Yisui Shengxue Granules

3. Psychiatric disorder.

4. Blood transfusion in the latest 90 days for severe β-Thalassemia; blood transfusion in the latest 45 days for intermediaβ-Thalassemia or intermedia α-Thalassemia.。

5. Upper respiratory tract infection with temperature higher than 38.5℃ in the latest 45 days.

6. Taking other antianemic agents in the latest 2 months.

7. Participation in any other clinical interventional trial in the latest 1 month.